Literature DB >> 1600052

The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin.

S W Sanders1, K G Tolman, P A Greski, D E Jennings, P A Hoyos, J G Page.   

Abstract

This study examined the effects of dose and time of administration of lansoprazole on gastric pH and serum gastrin in healthy male volunteers. Three groups of six subjects received 10, 20 or 60 mg doses of lansoprazole or placebo. Doses were administered at 22.00 hours daily for 7 days. An additional 18 subjects received once daily 30 mg oral doses of lansoprazole or placebo; these subjects were dosed at either 08.00 hours or 22.00 hours in a randomized, crossover fashion with a 2-week washout period. Gastric pH was monitored for 24 h following the first and final dose, and 1 week following the completion of dosing. Lansoprazole, at all doses except 20 mg/day, significantly increased the median 24-hour gastric pH following 7 days of dosing (P less than 0.05). In addition, morning dosing in the 30-mg crossover group led to a higher 24-h median pH than evening dosing (P = 0.003). There was no difference in night-time median pH between morning and evening dosing. Morning dosing also led to a significant increase in gastric pH on study Day 1 (P less than 0.05). Plasma concentrations of lansoprazole were highly variable between subjects, but there was a significant correlation between AUC and the median 24-h gastric pH. Plasma concentrations and AUCs were higher on Day 7 than on Day 1 for subjects receiving 10 or 20 mg, but not for those receiving 30 or 60 mg doses. Lansoprazole bioavailability demonstrated a circadian effect manifested by higher plasma concentrations following morning dosing. Serum gastrin concentrations were elevated in all active medication groups.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600052     DOI: 10.1111/j.1365-2036.1992.tb00057.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

Review 2.  Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.

Authors:  Fabio Baldi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

4.  Ion flow regulates left-right asymmetry in sea urchin development.

Authors:  Taku Hibino; Yuichiro Ishii; Michael Levin; Atsuo Nishino
Journal:  Dev Genes Evol       Date:  2006-03-14       Impact factor: 0.900

5.  Effect of proton pump inhibitors on glycemic control in patients with diabetes.

Authors:  Kohzo Takebayashi; Toshihiko Inukai
Journal:  World J Diabetes       Date:  2015-08-25

Review 6.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

7.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Authors:  David Y Graham; Aylin Tansel
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-28       Impact factor: 11.382

Review 8.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 9.  Proton pump inhibitory therapy: then and now.

Authors:  W Schepp
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

Review 10.  Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review.

Authors:  Agnieszka Wiesner; Małgorzata Zwolińska-Wcisło; Paweł Paśko
Journal:  Int J Environ Res Public Health       Date:  2021-03-29       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.